Linked Life Data

21546220

Source:http://linkedlifedata.com/resource/pubmed/id/21546220

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2011-5-18
pubmed:abstractText
We aimed to assess the association between core cerebrospinal fluid (CSF) biomarkers, regional brain atrophy and clinical severity in the Alzheimer's disease (AD) continuum, as well as to investigate how cognitive reserve (CR) may modulate these putative associations. Forty-nine subjects (11 controls, 10 patients with subjective memory complaints, 19 with mild cognitive impairment and 9 mild AD) underwent lumbar puncture and high-resolution magnetic resonance imaging (MRI). CSF amyloid-?(1-42) (A?(1-42)), total tau (t-tau) and phosphorylated tau (p-tau(181)) were determined. Voxel-based morphometry (VBM) was applied and multiple regression analyses for the whole sample were carried out. Clinical severity was adjusted using the Clinical Dementia Rating Sum of Boxes score (CDR-SB). A negative correlation between t-tau levels and grey matter (GM) volume in temporo-parietal regions was found, regardless of CDR-SB score. In contrast, the negative correlation between p-tau(181) and GM volume was largely explained by clinical severity, except in the posterior cingulate cortex. CR did not significantly modify these correlations. A?(1-42) levels were not related to GM volume but were related to clinical severity, an association that was attenuated when CR was considered. In conclusion, the present findings reflect that t-tau CSF concentrations are associated with GM atrophy in neuropathologically relevant areas across the AD continuum, whereas the p-tau(181) association is largely dependent on the degree of clinical severity. The relationship between CSF A?(1-42) and clinical severity seems to be modulated by CR, suggesting that there may be subjects with pathological levels of A?(1-42) and high CR estimates who remain clinically asymptomatic.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0165-1781
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
pubmed:issnType
Print
pubmed:day
30
pubmed:volume
192
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
140-6
pubmed:meshHeading
pubmed-meshheading:21546220-Aged, pubmed-meshheading:21546220-Aged, 80 and over, pubmed-meshheading:21546220-Amyloid beta-Peptides, pubmed-meshheading:21546220-Atrophy, pubmed-meshheading:21546220-Brain, pubmed-meshheading:21546220-Brain Mapping, pubmed-meshheading:21546220-Cognition Disorders, pubmed-meshheading:21546220-Disease Progression, pubmed-meshheading:21546220-Female, pubmed-meshheading:21546220-Humans, pubmed-meshheading:21546220-Magnetic Resonance Imaging, pubmed-meshheading:21546220-Male, pubmed-meshheading:21546220-Middle Aged, pubmed-meshheading:21546220-Multivariate Analysis, pubmed-meshheading:21546220-Neuropsychological Tests, pubmed-meshheading:21546220-Peptide Fragments, pubmed-meshheading:21546220-Psychiatric Status Rating Scales, pubmed-meshheading:21546220-Questionnaires, pubmed-meshheading:21546220-Schizophrenia, pubmed-meshheading:21546220-Statistics as Topic, pubmed-meshheading:21546220-tau Proteins
pubmed:year
2011
pubmed:articleTitle
Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.
pubmed:affiliation
Alzheimer's disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Catalonia, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't